Search

Search Constraints

You searched for: Author/Creator Culp, Meredith

Search Results

1. [P1–059]: APPROACHES TO SUBJECT RETENTION IN A PHASE 3 DELAY‐OF‐ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER's DISEASE (MCI‐AD) CLINICAL TRIAL: THE TOMMORROW STUDY EXPERIENCE. (1st July 2017)

2. P2‐083: Progress in the tommorrow study: A pharmacogenetics supported clinical trial to delay onset of mild cognitive impairment due to Alzheimer's disease with low‐dose pioglitazone. (1st July 2015)

3. P4‐383: Characterization of the Screened Population for the Tommorrow Study: a Pharmacogenetics‐Supported Clinical Trial to Delay the Onset of Mild Cognitive Impairment Due to Alzheimer'S Disease. (1st July 2016)

4. DT‐02‐02: TOMMORROW: RESULTS FROM A PHASE 3 TRIAL TO DELAY THE ONSET OF MCI DUE TO AD AND QUALIFY A GENETIC BIOMARKER ALGORITHM. (1st July 2019)

5. The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial. Issue 1 (1st January 2019)

6. O4‐11‐02: DEFINING COGNITION IN PRE‐DEMENTIA CLINICAL TRIALS: BASELINE NEUROPSYCHOLOGICAL DATA FROM THE TOMMORROW STUDY. (1st July 2019)

7. P1‐050: ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW STUDY: A DELAY‐OF‐ONSET PHASE 3 CLINICAL TRIAL. (1st July 2006)

8. A genetic enrichment strategy for delay of onset of Alzheimer's disease clinical trials: Biomarkers (non‐neuroimaging)/Use in clinical trial design and evaluation. (7th December 2020)

9. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Issue 7 (July 2021)